López CSM, Carranza MJ

Language: Spanish
References: 23
Page: 307-312
PDF size: 195.31 Kb.

ABSTRACT

Background: Menopause has been independently related to metabolic syndrome which has a high prevalence in Mexico. However there is not any trial that describes the features of metabolic syndrome in the menopause.
Objective: To determine the clinic, metabolic, vascular and mood features of climacteric and premenopausal women with metabolic syndrome.
Material and Methods: Sixty nine women with metabolic syndrome were recorded, 48 menopausal and 15 premenopausal, they were featured for weight, height, BMI, waist, blood pressure, fasting and postprandial glucose, fasting insulin, HOMA, lipid profile, clinical chemistry, haematology, Beck depression inventory, carotid intimae-media thickness and flow-dependent vasodilation.
Results: In menopausal women there is a greater frequency of disglucemia, insulin resistance, diabetes, carotid atherosclerosis and endothelial dysfunction. In premenopausal prevailed obesity, atherogenic dyslipidaemia and hypertension. There were a higher depression frequency in premenopausal women who showed more dissatisfaction, self punishment, deception and deterioration of their aspect feelings; while in menopausal women libido decrease was the predominant feature.
Conclusions: Metabolic syndrome is more frequent in menopausal women but it is more severe in premenopausal in which there is more insulin resistance.

REFERENCES

1. Rassouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321- 333.

2. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-275.

3. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. JCEM 2001;86:5457- 5464.

4. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135-1141.

5. Correti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery. J Am Coll Cardiol 2002;39:257-265.

6. Neunteufl T, Heher S, Katzenchlager R, Wolf G. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-210.

7. Al-Shali K, House AA, Hanley AJ, Khan HM, et al. Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis 2005;178:319-325.

8. Hegele RA, Al-Shali K, Khan HM, Hanley AJG, et al. Carotid ultrasound in one, two an three dimension. Vasc Dis Prevention2005;2:87-92.

9. Bech P. Rating scales for mood disorders: Applicability, consistency and construct validity. Acta Psychiatr Scand 1988;78(Suppl 345):45-55.

10. Conde V, Useros E. Adaptación castellana de la escala de evaluación conductual para la depresión de Beck. Rev Psiquiatr Psicol Med Eur Am 1975;12:217-236.

11. Conde López V, Franch Valverde JI. Escalas de evaluación comportamental para la cuantificación de la sintomatología psicopatológica en los trastornos angustiosos y depresivos. Trébol, 1984.

12. O’Brien E, Beevers G, Lip GYH. ABC of hypertension: Blood pressure measurement. BMJ 2001;322:1167-1170.

13. Pascot A, Despres JP, Lemieux I, Almeras N, et al. Deterioration of the metabolic risk profile in women. Respective contributions of impaired glucose tolerance and visceral fat accumulation. Diabetes Care 2001;24:902-908.

14. Mauriege P, Imbeault P, Prud’Homme D, Tremblay A, et al. Subcutaneous adipose tissue metabolism at menopause: importance of body fatness and regional fat distribution. J Clin Endocrinol Metab 2000;85:2446-2454.

15. Olaiz G, Rivera J, Shamah T, Rojas R, y col. Encuesta Nacional de Salud y Nutrición 2006 (ENSANUT 2006).

16. Carranza MJ, López CSM. El síndrome metabólico en México. Med Int Mex 2008;24(4):251-261.

17. Carranza-Madrigal J. Síndrome metabólico, disfunción endotelial, inflamación y microalbuminuria. En: Rubio-Guerra AF. Síndrome metabólico. 1ª ed. México: Nieto Editores, 2008;pp:19-27.

18. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321-331.

19. Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelín-Hernández G, y col. Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México: Resultados finales de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2003;73:62-77.

20. López CSM, Alveano HJ, Carranza MJ. Prevalencia de síntomas depresivos en síndrome metabólico. Rev Fac Nac Salud Pública 2008;26(2):124-133.

21. Dumbar JA, Reddy P, Davis-Lameloise N, Philpot B, et al. Depression: An important comorbidity with metabolic syndrome in a general population. Diabetes Care 2008;31:2368-2373.

22. Brown ES, Varghese FP, McEwen BS. Association of Depression with Medical Illness: Does Cortisol Play a Role? Biol Psychiatry 2004;55:1-9.

23. Vaccarino V, McClure C, Johnson D, Sheps DS, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosomatic Medicine 2008;70:40-48.